Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Thalidomide
Drug ID BADD_D02192
Description A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action. [PubChem]
Indications and Usage For the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). Also for use as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence.
Marketing Status Prescription
ATC Code L04AX02
DrugBank ID DB01041
KEGG ID D00754
MeSH ID D013792
PubChem ID 5426
TTD Drug ID D0U7GK
NDC Product Code 59572-205; 59572-210; 59572-220; 59572-215; 69988-0052; 63818-0424; 17337-0301; 68554-0011
Synonyms Thalidomide | Sedoval | Thalomid
Chemical Information
Molecular Formula C13H10N2O4
CAS Registry Number 50-35-1
SMILES C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Abdominal distension07.01.04.0010.008685%
Abdominal pain07.01.05.002--
Abdominal pain upper07.01.05.003--
Acne23.02.01.0010.002895%Not Available
Acquired immunodeficiency syndrome10.03.03.001; 11.05.17.007--Not Available
Acute leukaemia01.10.02.001; 16.01.02.001--Not Available
Acute lymphocytic leukaemia01.10.01.001; 16.01.01.0010.000604%Not Available
Acute myeloid leukaemia01.10.05.001; 16.01.05.0010.001208%Not Available
Acute myocardial infarction02.02.02.001; 24.04.04.001--Not Available
Acute respiratory distress syndrome22.01.03.0010.000604%
Ageusia07.14.03.003; 17.02.07.0010.002895%Not Available
Agitation17.02.05.012; 19.06.02.001--
Agranulocytosis01.02.03.001--Not Available
Alanine aminotransferase increased13.03.01.003--
Albuminuria20.02.01.001--Not Available
Alopecia23.02.02.001--
Altered state of consciousness17.02.04.001; 19.07.01.003--Not Available
Amblyopia06.02.01.001--Not Available
Amenorrhoea05.05.01.002; 21.01.02.001--
Ammonia increased13.03.01.0230.001158%Not Available
Amnesia17.03.02.001; 19.20.01.001--
Amyloidosis10.02.05.0010.000755%Not Available
Anaemia01.03.02.0010.020265%
Anaemia macrocytic01.03.02.002; 14.12.01.002--Not Available
Anaemia megaloblastic01.03.02.003; 14.12.01.003--Not Available
Anaphylactic reaction10.01.07.001; 24.06.03.006--
Angina pectoris02.02.02.002; 24.04.04.002--
Angioedema10.01.05.009; 23.04.01.001--Not Available
Ankle fracture12.04.01.005; 15.08.03.0050.001737%
The 1th Page    1 2 3 4 5    Next   Last    Total 24 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene